Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology PLLC, Nashville, TN.
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):752-765. doi: 10.1016/j.clml.2021.06.020. Epub 2021 Jun 26.
Relapsed and refractory multiple myeloma (RRMM) presents a therapeutic challenge due to the development of drug resistance. Panobinostat is an oral histone deacetylase inhibitor (HDACi) that affects multiple cellular pathways and has demonstrated the ability to resensitize refractory-multiple myeloma cells in preclinical studies, as well as in patients with RRMM in clinical trials. Synergy of panobinostat with a number of different classes of antimyeloma drugs (proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies) has also been shown. Panobinostat is a promising HDACi for the treatment of multiple myeloma. Here, we present a comprehensive review of preclinical and clinical studies of panobinostat.
复发和难治性多发性骨髓瘤（RRMM）由于耐药性的发展而带来治疗挑战。帕比司他是一种口服组蛋白去乙酰化酶抑制剂（HDACi），可影响多种细胞通路，并已在临床前研究以及 RRMM 患者的临床试验中证明有能力使耐药性多发性骨髓瘤细胞重新敏感。帕比司他与多种不同类别的抗骨髓瘤药物（蛋白酶体抑制剂、免疫调节药物和单克隆抗体）联合使用也显示出协同作用。帕比司他是一种很有前途的多发性骨髓瘤治疗 HDACi。在此，我们对帕比司他的临床前和临床研究进行了全面综述。
